Assembly Bio to launch four infectious disease trials in 2024

US-based biopharma Assembly Bio is planning to launch four clinical trials for its infectious disease pipeline candidates this year.

Assembly Bio CEO Jason Okazaki said the company hopes to initiate two trials in H1 and two in H2, focusing on herpes simplex virus 2 (HSV2), hepatitis B and hepatitis D (HDV).